Global /United Kingdom /Healthcare /Biotechnology /OBD
chevron_leftBack
Oxford BioDynamics Plc logo

Oxford BioDynamics Plc

OBD
LSE: OBD Delayed
0.2150GBX -2.3%
0.0029 USD
As of 5 June 2026, Oxford BioDynamics Plc has a market cap of $12.67M USD, ranking #39996 globally and #900 in the United Kingdom. It ranks #3564 in the Healthcare sector, and #698 in the Biotechnology industry.
Global Rank
39996
Country Rank
900
Sector Rank
3564
Industry Rank
698
Key Stats
Market Cap
$12.67MUSD
9.44M GBP
Enterprise Value
$17.67MUSD
13.16M GBP
Revenue (TTM)
$1.47MUSD
1.1M GBP
EBITDA (TTM)
-$13.78MUSD
-10.27M GBP
Net Income (TTM)
-$14.97MUSD
-11.15M GBP
PS Ratio
8.6
PB Ratio
8.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Jon Anthony Burrows open_in_new
Employees
41
Founded
2007
Website
oxfordbiodynamics.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-2.3% -13% 2.4% -25% -33% -51%
Upcoming Earnings
Earnings Date
Fri, Jun 5 Today

News

Loading...

Markets

Exchange Ticker Price
London Stock Exchange
MIC: XLON
PRIMARY
OBD
Oxford BioDynamics PLC
ISIN: GB00BD5H8572
Shares Out.:
4.291B1 Shares Float: 3.792B2
TV:
SA:
YF:
GF:
BA:
OBD
MS:
0.2150 GBX
OTC Markets
MIC: OTCM
OXBOF
Oxford BioDynamics PLC
ISIN: GB00BD5H8572
Shares Out.:
1.958B1 Shares Float: 1.67B2
TV:
SA:
YF:
GF:
BA:
MS:
0.0121 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Oxford BioDynamics Plc

Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarker. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch Orion, a cloud platform, running on google cloud architecture; and EpiSwitch Explorer Array Kit platform, enabling advanced analysis of 3D regulatory control points. The company was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.

Similar Companies

Industry: Biotechnology (United Kingdom)
Name
Market Cap diff.
PE
VRNA
$9.22B
73K%
-
$1.42B
11K%
-
CMPS
$1.13B
9K%
-
$975.48M
726.61M GBP
8K%
-
SLNCF
$265.93M
2K%
-
DXRX
$196.04M
146.03M GBP
1K%
-
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
AMGN
$182.42B
1M%
23.9
GILD
$159.92B
1M%
19.0
ARGX
$48.08B
41.39B EUR
379K%
39.9
$44.48B
68.19T KRW
351K%
35.5
CSL
$43.01B
60.27B AUD
339K%
29.3
LONN
$42.72B
33.71B CHF
337K%
37.2
chevron_leftBack